BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37725377)

  • 1. Ranitidine Use and Incident Cancer in a Multinational Cohort.
    You SC; Seo SI; Falconer T; Yanover C; Duarte-Salles T; Seager S; Posada JD; Shah NH; Nguyen PA; Kim Y; Hsu JC; Van Zandt M; Hsu MH; Lee HL; Ko H; Shin WG; Pratt N; Park RW; Reich CG; Suchard MA; Hripcsak G; Park CH; Prieto-Alhambra D
    JAMA Netw Open; 2023 Sep; 6(9):e2333495. PubMed ID: 37725377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Cancer in Association with Ranitidine and Nizatidine vs Other H2 Blockers: Analysis of the Japan Medical Data Center Claims Database 2005-2018.
    Iwagami M; Kumazawa R; Miyamoto Y; Ito Y; Ishimaru M; Morita K; Hamada S; Tamiya N; Yasunaga H
    Drug Saf; 2021 Mar; 44(3):361-371. PubMed ID: 33247391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between ranitidine use with potential NDMA impurities and risk of cancer in Korea.
    Joung KI; Hwang JE; Oh IS; Cho SI; Shin JY
    Sci Rep; 2022 Dec; 12(1):22396. PubMed ID: 36575247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histamine H2 receptor antagonist exposure was related to decreased all-cause mortality in critical ill patients with heart failure: a cohort study.
    Huang YH; Cai WK; Yin SJ; Wang P; Li ZR; Yang Q; Zhou T; Meng R; Yang M; Guo Y; He GH
    Eur J Prev Cardiol; 2022 Oct; 29(14):1854-1865. PubMed ID: 35707983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosage effects of histamine-2 receptor antagonist on the primary prophylaxis of non-steroidal anti-inflammatory drug (NSAID)-associated peptic ulcers: a retrospective cohort study.
    He Y; Chan EW; Man KK; Lau WC; Leung WK; Ho LM; Wong IC
    Drug Saf; 2014 Sep; 37(9):711-21. PubMed ID: 25096957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Utilisation Patterns of Alternatives to Ranitidine-Containing Medicines in Patients Treated with Ranitidine: A Network Analysis of Data from Six European National Databases.
    Arinze JT; de Ridder MAJ; Vojinovic D; van Ballegooijen H; Markov E; Duarte-Salles T; Rijnbeek P; Verhamme KMC
    Drug Saf; 2023 Dec; 46(12):1353-1362. PubMed ID: 37907775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Effectiveness and Safety of Oral Anticoagulants by Dementia Status in Older Patients With Atrial Fibrillation.
    Lin KJ; Singer DE; Bykov K; Bessette LG; Mastrorilli JM; Cervone A; Kim DH
    JAMA Netw Open; 2023 Mar; 6(3):e234086. PubMed ID: 36976562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study.
    Park J; You SC; Cho J; Park CH; Shin WG; Park RW; In Seo S
    BMC Pharmacol Toxicol; 2022 Jan; 23(1):9. PubMed ID: 35039078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study.
    Shin GY; Park JM; Hong J; Cho YK; Yim HW; Choi MG
    Am J Gastroenterol; 2021 Jun; 116(6):1211-1219. PubMed ID: 34074826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ranitidine and Risk of Bladder and Kidney Cancer: A Population-Based Cohort Study.
    Nørgaard M; Andersen IT; Heide-Jørgensen U; Erichsen R; Rees JR; Karagas MR; Sørensen HT
    Cancer Epidemiol Biomarkers Prev; 2022 Jan; 31(1):45-50. PubMed ID: 34649959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model.
    Seo SI; You SC; Park CH; Kim TJ; Ko YS; Kim Y; Yoo JJ; Kim J; Shin WG
    J Gastroenterol Hepatol; 2020 Aug; 35(8):1325-1330. PubMed ID: 31970824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranitidine Use and Risk of Upper Gastrointestinal Cancers.
    Adami HO; Trolle Andersen I; Heide-Jørgensen U; Chang ET; Nørgaard M; Sørensen HT
    Cancer Epidemiol Biomarkers Prev; 2021 Dec; 30(12):2302-2308. PubMed ID: 34620629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Cancer Following the Use of N-Nitrosodimethylamine (NDMA) Contaminated Ranitidine Products: A Nationwide Cohort Study in South Korea.
    Yoon HJ; Kim JH; Seo GH; Park H
    J Clin Med; 2021 Jan; 10(1):. PubMed ID: 33466237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of histamine-2 receptor antagonists as short-term therapy for gastro-esophageal reflux disease: a network meta-analysis.
    Zhao F; Wang S; Liu L; Wang Y
    Int J Clin Pharmacol Ther; 2016 Oct; 54(10):761-70. PubMed ID: 27443665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoepidemiological Research on N-Nitrosodimethylamine-Contaminated Ranitidine Use and Long-Term Cancer Risk: A Population-Based Longitudinal Cohort Study.
    Wang CH; Chen II; Chen CH; Tseng YT
    Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug usage evaluation: H2-receptor antagonist use in 30 hospitals.
    Kowalsky SF; Hamilton RA; Figge HL
    Hosp Formul; 1991 Sep; 26(9):725-6, 732, 734-6 passim. PubMed ID: 10114004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescription changes in patients with gastrointestinal disorders after withdrawal of ranitidine: a nationwide population-based cohort study.
    Ku M; Je NK
    Curr Med Res Opin; 2023 Feb; 39(2):197-203. PubMed ID: 36519289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rebound hypersecretion after H2-antagonist withdrawal--a comparative study with nizatidine, ranitidine and famotidine.
    Fullarton GM; Macdonald AM; McColl KE
    Aliment Pharmacol Ther; 1991 Aug; 5(4):391-8. PubMed ID: 1685675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposure to Ranitidine and Risk of Bladder Cancer: A Nested Case-Control Study.
    Cardwell CR; McDowell RD; Hughes CM; Hicks B; Murchie P
    Am J Gastroenterol; 2021 Aug; 116(8):1612-1619. PubMed ID: 34028367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.